A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT04222972 · TERMINATED

Trial details

NCT number: NCT04222972
Sponsor: Hoffmann-La Roche
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

RET-fusion Non Small Cell Lung Cancer Lung Neoplasm Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Disease Carcinoma, Bronchogenic Bronchial Diseases Head and Neck Neoplasms

Start date: 2020-07-24
Primary completion: 2025-01-27
Enrollment: 223

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.